Bacteroides dorei BDX-01 alleviates DSS-induced experimental colitis in mice by regulating intestinal bile salt hydrolase activity and the FXR-NLRP3 signaling pathway
Open accessThe DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index; 10 of the 22 sources its claims cite were checked for support.
Abstract
Background: The relationships among intestinal dysbiosis, bile acid (BA) metabolism disorders, and ulcerative colitis pathogenesis are now recognized. However, how specific strains regulate BA metabolism to alleviate colitis is still unclear. This study investigated the effects of Bacteroides dorei on the development of acute colitis and elucidated the underlying mechanisms. Methods: The safety of BDX-01 was evaluated in vitro and in vivo . 2.5% dextran sulfate sodium (DSS) induced colitis in C57BL/6 mice, Caco-2, and J774A.1 cells were used to evaluate the anti-inflammatory effect of BDX-01. qPCR and Western blotting were used to detect the expression of inflammatory pathways. Microbiota composition was analyzed by 16S rRNA gene sequencing. Enzyme activity analysis and targeted metabolomics were used to analyze fecal bile salt hydrolase (BSH) and BA levels. Antibiotic-induced pseudo-germ-free mice were used to investigate the role of gut microbiota in the alleviation of colitis by BDX-01. Results: We confirmed the safety of novel strain Bacteroides dorei BDX-01 in vitro and in vivo . Oral BDX-01 administration significantly ameliorated the symptoms and pathological damage of DSS-induced acute colitis. Moreoever, 16S rRNA sequencing and enzyme activity analysis showed that BDX-01 treatment increased intestinal BSH activity and the abundance of bacteria harboring this enzyme. Targeted metabolomics revealed that BDX-01 significantly increased intestinal BA excretion and deconjugation. Certain BAs act as FXR agonists. The β-muricholic acid (βMCA): taurine β-muricholic acid (T-βMCA) and cholic acid (CA): taurocholic acid (TCA) ratios and the deoxycholic acid (DCA) level decreased markedly in the colitis models but increased substantially in BDX-01-treated mice. The colonic farnesoid X receptor (FXR) and fibroblast growth factor 15 (FGF15) were upregulated in mice treated with BDX-01. BDX-01 downregulated the expression of colonic proinflammatory cytokines pyrin domain-containing 3 (NLRP3), ASC, cleaved caspase-1, and IL-1β. Antibiotic treatment didn’t abolish the protective effect of BDX-01 on colitis. In vitro studies showed TβMCA abolished the effects of BDX-01 on FXR activation and inhibition of the NLRP3 inflammasome activation. Conclusion: BDX-01 improved DSS-induced acute colitis by regulating intestinal BSH activity and the FXR-NLRP3 signaling pathway. Our findings indicate that BDX-01 is a promising probiotic to improve the management of ulcerative colitis.
Overview
CoChat Summary
TL;DR
Bacteroides dorei BDX-01, a strain isolated from healthy human stool, alleviated DSS-induced acute colitis in mice and showed no evident toxicity in vitro or in vivo. The paper argues that its benefit comes from increasing intestinal bile salt hydrolase (BSH) activity and activating the FXR-NLRP3 pathway, with effects also seen in cell experiments and in microbiota-depleted mice.
Key findings
- BDX-01 was identified as a novel B. dorei strain with 99% 16S rRNA sequence similarity to B. dorei 175 and 99.97% ANI; its complete genome was 5,521,745 bp with 42.01% GC content.
- Safety testing found no significant cytotoxicity in IEC-6 and Caco-2 cells (p > 0.05), no treatment-related toxicity in mice, and no significant differences in blood or liver/kidney indices; no histopathological injury was observed in stomach, colon, liver, or spleen.
- In DSS colitis mice, BDX-01 reduced weight loss, colon shortening, DAI, and histopathology score; the Model group histopathology score was 8.00 ± 0.71 versus 4.80 ± 0.84 with BDX-01 and 5.40 ± 0.89 with mesalazine.
- BDX-01 increased intestinal BSH activity and altered bile acid metabolism, including higher CA/TCA and βMCA/TβMCA ratios and higher DCA; it also upregulated colonic FXR and FGF15 and downregulated NLRP3, ASC, cleaved caspase-1, and IL-1β.
- Antibiotic depletion of gut microbiota did not abolish protection: Abx + DSS + BDX-01 mice still had reduced body-weight loss, DAI, colon damage, and histology scores, while FXR and FGF15 increased and NLRP3/IL-1β decreased.
- In Caco-2 cells and J774A.1 macrophages, BDX-01 suppressed TNF-α/LPS-induced Nlrp3 and Il-1β, and the effect was blocked by the FXR antagonist T-βMCA; the culture supernatant, not intact cells, upregulated Fxr and downregulated Nlrp3/Il-1β.
Methods
- The study combined strain identification and safety profiling (16S rRNA, whole-genome sequencing, virulence/resistance annotation, antibiotic susceptibility, cell cytotoxicity, and mouse toxicity tests) with an acute DSS colitis model in C57BL/6J mice.
- Mice received oral BDX-01, mesalazine, or controls; additional groups used antibiotic pretreatment to deplete microbiota. The paper also used Caco-2 cells and J774A.1 macrophages, plus TNF-α/LPS, FXR agonist GW4064, FXR antagonist T-βMCA, live/heat-killed bacteria, and culture supernatant.
- Main analyses included histology, DAI, qRT-PCR, western blotting, 16S rRNA microbiome sequencing, fecal BSH activity assays, targeted bile acid metabolomics by UHPLC-MS/MS, and correlation analysis.
Limitations
- The paper explicitly states that the acute DSS colitis model mainly reflects innate immunity and that the effect of BDX-01 on adaptive immunity will need to be explored in other IBD models.
- The authors also state that the active components in BDX-01 responsible for the anti-colitis effect were not identified.
- Evident from the text: the mechanistic conclusions are based on a mouse acute colitis model and cell culture experiments, so direct clinical efficacy in humans is not established.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures









Verification
Claims the paper makes
9 Valid · 1 Not valid · 7 Not checked · 82 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The gut microbiota of patients with IBD is characterized by low BSH activity”
- Also stated in: § 1 Introduction · plain
“The gut microbiota of patients with IBD is characterized by low BSH activity (Ogilvie and Jones, 2012; Duboc et al., 2013).”
§ Bacteroides dorei BDX-01 alleviates DSS-induced experimental colitis in mice by regulating intestinal bile salt hydrolase activity and the FXR-NLRP3 signaling pathway > 1 Introduction
What the sources say
- Partly supportedcites Ogilvie and Jones, 2012 matched to “Dysbiosis modulates capacity for bile acid modification in the gut microbiomes of patients with inflammatory bowel disease: a mechanism and marker of disease?: Figure 1” (2012) sourceExperimental — accuracy not yet measured
The paper’s discussion of Figure 1 reports reduced total abundance of BSH-like sequences and a significant reduction in Firmicutes-affiliated sequences in the Crohn’s disease group. It measures gene-sequence abundance in silico, not BSH activity directly, and does not establish low activity across all patients with IBD. (LLM, conf=0.86)
- Not checked — no full text of the sourcecites Duboc et al., 2013 matched to “Connecting dysbiosis, bile-acid dysmetabolism and gut inflammation in inflammatory bowel diseases” (2013) source
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § 1 Introduction · plain
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“B. Dorei possesses high BSH activity in vitro (Yao et al., 2018)”
§ Bacteroides dorei BDX-01 alleviates DSS-induced experimental colitis in mice by regulating intestinal bile salt hydrolase activity and the FXR-NLRP3 signaling pathway > 1 Introduction
What the sources say
- Partly supportedcites Yao et al., 2018 matched to “A selective gut bacterial bile salt hydrolase alters host metabolism” (2018) sourceExperimental — accuracy not yet measured
The Materials and methods list two Bacteroides dorei strains, and the Results describe an in vitro BSH-activity screen of the Bacteroidetes strains. The text available for that screen does not state that B. dorei had high activity; that degree of activity is unsupported. (LLM, conf=0.76)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“BA metabolism is defective in patients with IBD, as indicated by increased levels of primary BAs (PBAs) and/or their conjugated forms, accompanied by decreased levels of second BAs (SBAs) (Lavelle and Sokol, 2020; Biagioli et al., 2021; Gallagher et al., 2021).”
§ Bacteroides dorei BDX-01 alleviates DSS-induced experimental colitis in mice by regulating intestinal bile salt hydrolase activity and the FXR-NLRP3 signaling pathway > 1 Introduction
What the sources say
- Not checked — no full text of the sourcecites Lavelle and Sokol, 2020 matched to “Gut microbiota-derived metabolites as key actors in inflammatory bowel disease” (2020) source
- Partly supportedcites Biagioli et al., 2021 matched to “Bile acids activated receptors in inflammatory bowel disease” (2021) sourceExperimental — accuracy not yet measured
Section 6 reports increased primary and decreased secondary bile acids in patients with active IBD, and increased conjugated and decreased secondary bile-acid excretion during UC flares. It ties these patterns to active disease or particular forms of IBD, rather than establishing the full pattern for all patients with IBD. (LLM, conf=0.84)
- Partly supportedcites Gallagher et al., 2021 matched to “Metabolomic analysis in inflammatory bowel disease: A systematic review” (2021) sourceExperimental — accuracy not yet measured
The Stool metabolomics studies section (p. 15) reports increased primary or conjugated bile acids alongside decreased secondary bile acids in dysbiotic Crohn’s disease samples. But it also reports two studies finding lower levels of both primary and secondary bile acids in IBD patients than controls, so the claimed pattern is not supported as a general finding across patients with IBD. (LLM, conf=0.88)
hedgedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Bile acids (BAs) are microbiota-associated metabolites that regulate intestinal homeostasis and inflammation in UC (Kriaa et al., 2022).”
§ Bacteroides dorei BDX-01 alleviates DSS-induced experimental colitis in mice by regulating intestinal bile salt hydrolase activity and the FXR-NLRP3 signaling pathway > 1 Introduction
What the sources say
- Supportedcites Kriaa et al., 2022 matched to “Bile acids: Key players in inflammatory bowel diseases?” (2022) source
The Introduction identifies UC as an inflammatory bowel disease and describes bile acids’ interactions with gut microbiota and their role in regulating intestinal inflammation. The Conclusions state that microbial bile-acid metabolism shapes host physiology and that altered bile-acid metabolism and signaling influence intestinal homeostasis in IBDs, which includes UC. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“A fecal bile acid analysis revealed that BDX-01 treatment significantly altered the fecal BA profile (Figure 5A).”
§ Bacteroides dorei BDX-01 alleviates DSS-induced experimental colitis in mice by regulating intestinal bile salt hydrolase activity and the FXR-NLRP3 signaling pathway > 3 Results > 3.5 BDX-01 affected bile acid metabolism and activated FXR in the colons of mice with DSS-induced colitis
states a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: unclear — It is unclear why the paper says it holds.
42 more claims
Create a free account to see all 99 claims and every source verdict.
- Probably not a substantial claim. 15
- It may state two separate claims as one. 39
- The quote only partly states this claim. 5
Citations
Cites
Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method
Livak, K. J., & Schmittgen, T. D. (2001) · Methods · doi:10.1006/meth.2001.1262 · Cited by 180,860 · cited 1×
“Each sample was detected in triplicate 10-μL reaction volumes and assessed using the comparative cycle (2−ΔΔCT) method (Livak and Schmittgen, 2001).”
MethodQIIME allows analysis of high-throughput community sequencing data
Caporaso, J. G., Kuczynski, J., Stombaugh, J., Bittinger, K., Bushman, F. D., Costello, E. K., Fierer, N., Peña, A. G., Goodrich, J. K., Gordon, J. I., et al. (2010) · Nature Methods · doi:10.1038/nmeth.f.303 · Cited by 34,887 · cited 1×
“Then, representative sequences were selected using the QIIME software from each OTU, which were aligned and annotated based on the SILVA database (v138) (Caporaso et al., 2010).”
MethodUPARSE: highly accurate OTU sequences from microbial amplicon reads
Edgar, R. C. (2013) · Nature Methods · doi:10.1038/nmeth.2604 · Cited by 16,707 · cited 1×
“Paired end reads were merged via the rapid length adjustment of short reads, followed by sequence analysis using UPARSE (Edgar, 2013).”
MethodFLASH: fast length adjustment of short reads to improve genome assemblies
Magoč, T., & Salzberg, S. L. (2011) · Bioinformatics · doi:10.1093/bioinformatics/btr507 · Cited by 15,366 · cited 1×
“Subsequently, sequences with ≥97% similarity were subsequently assigned to the same operational taxonomic units (OTUs) (Magoč and Salzberg, 2011).”
Abraham, C., & Cho, J. H. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0804647 · Cited by 2,712
CARD 2017: expansion and model-centric curation of the comprehensive antibiotic resistance database
Jia, B., Raphenya, A. R., Alcock, B., Waglechner, N., Guo, P., Tsang, K. K., Lago, B. A., Dave, B. M., Pereira, S., Sharma, A. N., et al. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkw1004 · Cited by 2,661 · cited 3×
“…resistance genes were annotated by BLAST analysis with genes in the Virulence Factors of Pathogenic Bacteria Database (VFDB) (Chen et al., 2005) and Comprehensive Antibiotic Resistance Database (CARD) (Jia et al., 2017), based on a minimum of 50% and 35% amino acid homology, respectively.”
BackgroundMethodA microbial symbiosis factor prevents intestinal inflammatory disease
Mazmanian, S. K., Round, J. L., & Kasper, D. L. (2008) · Nature · doi:10.1038/nature07008 · Cited by 2,340 · cited 13×
“IBD includes two types: ulcerative colitis (UC) and Crohn’s disease (CD), both of which are associated with gut dysbiosis that occurs after the intestinal microbiota undergoes compositional and metabolic changes (Ni et al., 2017; Shen et al., 2018).”
BackgroundInfluentialSayin, S. I., Wahlström, A., Felin, J., Jäntti, S., Marschall, H.-U., Bamberg, K., Angelin, B., Hyötyläinen, T., Orešič, M., & Bäckhed, F. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.01.003 · Cited by 2,331 · cited 1×
“The gut microbiota may inhibit the synthesis of BAs by decreasing the level of TβMCA, an FXR antagonist (Sayin et al., 2013).”
BackgroundVFDB: a reference database for bacterial virulence factors
Chen, L. (2004) · Nucleic Acids Research · doi:10.1093/nar/gki008 · Cited by 2,097 · cited 3×
“According to the blast analysis of the VFDB database, 14 virulence factor homologs were identified in BDX-01 genome (Table 1), most of which correlate with cellular structure or physiological activities, and none have been reported as the pathogenesis of B. dorei.”
MethodDextran Sulfate Sodium (DSS)‐Induced Colitis in Mice
Chassaing, B., Aitken, J. D., Malleshappa, M., & Vijay‐Kumar, M. (2014) · Current Protocols in Immunology · doi:10.1002/0471142735.im1525s104 · Cited by 2,090 · cited 1×
“For the acute colitis experiment, colitis induction was performed as previously described with slight modifications (Chassaing et al., 2014).”
MethodGut microbiota-derived metabolites as key actors in inflammatory bowel disease
Lavelle, A., & Sokol, H. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0258-z · Cited by 2,015
Bile acid-microbiota crosstalk in gastrointestinal inflammation and carcinogenesis
Jia, W., Xie, G., & Jia, W. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.119 · Cited by 1,924 · cited 1×
“Although there is some controversy regarding the rank order of the FXR-activating potentials of bile acids, there is a consensus that unconjugated bile acids have greater potential to activate FXR than conjugated bile acids, possibly due to the greater lipophilicity of unconjugated bile acids (Jia et al., 2018).”
BackgroundFibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis
Inagaki, T., Choi, M., Moschetta, A., Peng, L., Cummins, C. L., McDonald, J. G., Luo, G., Jones, S. A., Goodwin, B., Richardson, J. A., et al. (2005) · Cell Metabolism · doi:10.1016/j.cmet.2005.09.001 · Cited by 1,865 · cited 1×
“In the ileum, FXRparticipates in BA reabsorption by regulating the expression of BA transporters and induces the secretion of fibroblast growth factor-19/15, which is delivered to the liver via the portal vein to suppress CYP7A1 expression (Inagaki et al., 2005).”
BackgroundGut microbiota and IBD: causation or correlation?
Ni, J., Wu, G. D., Albenberg, L., & Tomov, V. T. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.88 · Cited by 1,778 · cited 2×
“However, relatively little is known about the impact of the gut microbiota on this disorder (Ni et al., 2017; Pittayanon et al., 2020).”
BackgroundChemically induced mouse models of acute and chronic intestinal inflammation
Wirtz, S., Popp, V., Kindermann, M., Gerlach, K., Weigmann, B., Fichtner-Feigl, S., & Neurath, M. F. (2017) · Nature Protocols · doi:10.1038/nprot.2017.044 · Cited by 1,575 · cited 1×
“First, the acute DSS colitismodel is useful for analyzing innate immunemechanisms in the context of colitis (Wirtz et al., 2017), we will further explore the effect of BDX-01 on adaptive immunity with the help of other IBD models.”
BackgroundShamu, C. E., & Walter, P. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00666.x · Cited by 1,264
Jones, B. V., Begley, M., Hill, C., Gahan, C. G. M., & Marchesi, J. R. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0804437105 · Cited by 1,098 · cited 1×
“Gut microbiota analyses revealed that Firmicutes, Actinobacteria, and Erysipelotrichaceae have high BSH activity (Jones et al., 2008; Labbé et al., 2014).”
BackgroundGut microbiota and intestinal FXR mediate the clinical benefits of metformin
Sun, L., Xie, C., Wang, G., Wu, Y., Wu, Q., Wang, X., Liu, J., Deng, Y., Xia, J., Chen, B., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0222-4 · Cited by 1,011
Connecting dysbiosis, bile-acid dysmetabolism and gut inflammation in inflammatory bowel diseases
Duboc, H., Rajca, S., Rainteau, D., Benarous, D., Maubert, M.-A., Quervain, E., Thomas, G., Barbu, V., Humbert, L., Despras, G., et al. (2013) · Gut · doi:10.1136/gutjnl-2012-302578 · Cited by 930 · cited 2×
“The gut microbiota of patients with IBD is characterized by low BSH activity (Ogilvie and Jones, 2012; Duboc et al., 2013).”
BackgroundGadaleta, R. M., van Erpecum, K. J., Oldenburg, B., Willemsen, E. C. L., Renooij, W., Murzilli, S., Klomp, L. W. J., Siersema, P. D., Schipper, M. E. I., Danese, S., et al. (2011) · Gut · doi:10.1136/gut.2010.212159 · Cited by 870
Li, F., Jiang, C., Krausz, K. W., Li, Y., Albert, I., Hao, H., Fabre, K. M., Mitchell, J. B., Patterson, A. D., & Gonzalez, F. J. (2013) · Nature Communications · doi:10.1038/ncomms3384 · Cited by 705 · cited 1×
“TβMCA inhibited the FXR signaling pathway in the presence of FXR agonists TCA and TCDCA (Li et al., 2013).”
BackgroundYin, J., Liao, S., He, Y., Wang, S., Xia, G., Liu, F., Zhu, J., You, C., Chen, Q., Zhou, L., et al. (2015) · Journal of the American Heart Association · doi:10.1161/jaha.115.002699 · Cited by 669 · cited 1×
“) according to operating instructions (Yin et al., 2015).”
The bile acid receptor FXR is a modulator of intestinal innate immunity
Vavassori, P., Mencarelli, A., Renga, B., Distrutti, E., & Fiorucci, S. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0803978 · Cited by 655 · cited 1×
“FXR is implicated in intestinal immunomodulation and barrier function (Vavassori et al., 2009).”
BackgroundNLRP3 Inflammasome and Inflammatory Bowel Disease
Zhen, Y., & Zhang, H. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00276 · Cited by 649 · cited 1×
“It triggers caspase-1 activation and IL-1β and IL-18 secretion and participates in the development of UC (Zhen and Zhang, 2019).”
BackgroundShen, Z.-H., Zhu, C.-X., Quan, Y.-S., Yang, Z.-Y., Wu, S., Luo, W.-W., Tan, B., & Wang, X.-Y. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i1.5 · Cited by 646 · cited 2×
“Gut microbiota disturbances increase the content of harmful bacteria and dysregulate gut homeostasis (Shen et al., 2018).”
BackgroundPittayanon, R., Lau, J. T., Leontiadis, G. I., Tse, F., Yuan, Y., Surette, M., & Moayyedi, P. (2020) · Gastroenterology · doi:10.1053/j.gastro.2019.11.294 · Cited by 623 · cited 1×
“However, relatively little is known about the impact of the gut microbiota on this disorder (Ni et al., 2017; Pittayanon et al., 2020).”
BackgroundYoshida, N., Emoto, T., Yamashita, T., Watanabe, H., Hayashi, T., Tabata, T., Hoshi, N., Hatano, N., Ozawa, G., Sasaki, N., et al. (2018) · Circulation · doi:10.1161/circulationaha.118.033714 · Cited by 619 · cited 2×
“, 2021), mitigate atherosclerosis, and suppress proinflammatory cytokine production (Yoshida et al., 2018).”
BackgroundEpithelial cells as sensors for microbial infection.
Kagnoff, M. F., & Eckmann, L. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119522 · Cited by 615 · cited 1×
“Enterocytes secrete cytokines and chemokines that promote macrophage and immunocyte infiltration into intestinal inflammatory sites (Kagnoff and Eckmann, 1997).”
BackgroundBian, X., Wu, W., Yang, L., Lv, L., Wang, Q., Li, Y., Ye, J., Fang, D., Wu, J., Jiang, X., et al. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.02259 · Cited by 530 · cited 1×
“However, the mesalazine group could significantly increase the abundance of Akkermansia and Lachnoclostridium, two beneficial bacteria negatively correlated with UC activity (Wang et al., 2018; Bian et al., 2019).”
BackgroundInteractions between gut bacteria and bile in health and disease
Long, S. L., Gahan, C. G. M., & Joyce, S. A. (2017) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2017.06.002 · Cited by 495 · cited 1×
“BA transformation by BSH-competent bacteria determines the magnitude of BA-induced nuclear FXR activation in the gut (Long et al., 2017; Sun et al., 2018).”
BackgroundRole of bile acids and their receptors in gastrointestinal and hepatic pathophysiology
Fuchs, C. D., & Trauner, M. (2022) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00566-7 · Cited by 490
Farnesoid X Receptor Regulation of the NLRP3 Inflammasome Underlies Cholestasis-Associated Sepsis
Hao, H., Cao, L., Jiang, C., Che, Y., Zhang, S., Takahashi, S., Wang, G., & Gonzalez, F. J. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.03.007 · Cited by 469 · cited 1×
“The FXR agonism exert anti-inflammatory effects by inhibiting inflammatory signaling pathways, including the NF-κB signaling pathway and the NLRP3 inflammasome signaling pathway (Gadaleta et al., 2011; Hao et al., 2017).”
BackgroundDavis-Richardson, A. G., Ardissone, A. N., Dias, R., Simell, V., Leonard, M. T., Kemppainen, K. M., Drew, J. C., Schatz, D., Atkinson, M. A., Kolaczkowski, B., et al. (2014) · Frontiers in Microbiology · doi:10.3389/fmicb.2014.00678 · Cited by 308 · cited 1×
“dorei in different disease models is also controversial (Sánchez et al., 2010; Davis-Richardson et al., 2014; Davis-Richardson and Triplett, 2015; Zhang et al., 2015; Yao et al., 2018; Yoshida et al., 2018; Song et al., 2021).”
BackgroundMutations in the nuclear bile acid receptor FXR cause progressive familial intrahepatic cholestasis
Gomez-Ospina, N., Potter, C. J., Xiao, R., Manickam, K., Kim, M.-S., Kim, K. H., Shneider, B. L., Picarsic, J. L., Jacobson, T. A., Zhang, J., et al. (2016) · Nature Communications · doi:10.1038/ncomms10713 · Cited by 300 · cited 1×
“Farnesoid X receptor (FXR) is a member of the steroid/thyroid hormone receptor family of ligand-activated transcription factors (Gomez-Ospina et al., 2016).”
BackgroundEmerging roles of bile acids in mucosal immunity and inflammation
Chen, M. L., Takeda, K., & Sundrud, M. S. (2019) · Mucosal Immunology · doi:10.1038/s41385-019-0162-4 · Cited by 298
Jang, Y. J., Kim, W.-K., Han, D. H., Lee, K., & Ko, G. (2019) · Gut Microbes · doi:10.1080/19490976.2019.1589281 · Cited by 296 · cited 2×
“Changes in disease activity index (DAI) were assessed as previously described (Jang et al., 2019) according to the following criteria: (1) weight loss (%), (2) stool consistency, and (3) fecal blood (Supplementary Table S1).”
BackgroundMethodFocus on the Role of NLRP3 Inflammasome in Diseases
Fusco, R., Siracusa, R., Genovese, T., Cuzzocrea, S., & Di Paola, R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124223 · Cited by 290 · cited 1×
“The NLRP3 inflammasome is ubiquitous among epithelial cells and immunocytes (Fusco et al., 2020).”
BackgroundRyan, F. J., Ahern, A. M., Fitzgerald, R. S., Laserna-Mendieta, E. J., Power, E. M., Clooney, A. G., O’Donoghue, K. W., McMurdie, P. J., Iwai, S., Crits-Christoph, A., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15342-5 · Cited by 285 · cited 12×
“IBD includes two types: ulcerative colitis (UC) and Crohn’s disease (CD), both of which are associated with gut dysbiosis that occurs after the intestinal microbiota undergoes compositional and metabolic changes (Ni et al., 2017; Shen et al., 2018).”
BackgroundInfluentialA selective gut bacterial bile salt hydrolase alters host metabolism
Yao, L., Seaton, S. C., Ndousse-Fetter, S., Adhikari, A. A., DiBenedetto, N., Mina, A. I., Banks, A. S., Bry, L., & Devlin, A. S. (2018) · eLife · doi:10.7554/elife.37182 · Cited by 274 · cited 2×
“Dorei possesses high BSH activity in vitro (Yao et al., 2018), and its metabolites regulate the expression of genes involved in FXR and BA homeostasis in a gene- and tissue-specific manner in dietinduced obese mice (Zhang et al.”
BackgroundPrevalence of Bacteroides and Prevotella spp. in ulcerative colitis
Lucke, K., Miehlke, S., Jacobs, E., & Schuppler, M. (2006) · Journal of Medical Microbiology · doi:10.1099/jmm.0.46198-0 · Cited by 262 · cited 1×
“Bacteroides is a dominant and biologically important commensal bacteria in the human colon, and its relative abundance increases markedly in the mucosal tissue of patients with UC (Lucke et al., 2006).”
BackgroundD'Aimmo, M. R., Modesto, M., & Biavati, B. (2007) · International Journal of Food Microbiology · doi:10.1016/j.ijfoodmicro.2006.10.003 · Cited by 195 · cited 1×
“Based on the clinical resistance classification, its MIC was >32 μg/mL (D’Aimmo et al., 2007).”
BackgroundBacteroides thetaiotaomicron Ameliorates Colon Inflammation in Preclinical Models of Crohn’s Disease
Delday, M., Mulder, I., Logan, E. T., & Grant, G. (2019) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izy281 · Cited by 193 · cited 13×
“IBD includes two types: ulcerative colitis (UC) and Crohn’s disease (CD), both of which are associated with gut dysbiosis that occurs after the intestinal microbiota undergoes compositional and metabolic changes (Ni et al., 2017; Shen et al., 2018).”
BackgroundInfluentialThe Emerging Role of Bile Acids in the Pathogenesis of Inflammatory Bowel Disease
Thomas, J. P., Modos, D., Rushbrook, S. M., Powell, N., & Korcsmaros, T. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.829525 · Cited by 156 · cited 1×
“Animal and human studies have revealed that the role of the NLRP3 inflammasome in the pathogenesis of IBD remains unclear (Thomas et al., 2022); in this study, we found that hyperactivation of intestinal NF-κB and NLRP3 aggravated experimental colitis in mice.”
BackgroundThe human microbiome and bile acid metabolism: Dysbiosis, dysmetabolism, disease and intervention
Jones, M. L., Martoni, C. J., Ganopolsky, J. G., Labbé, A., & Prakash, S. (2014) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2014.880420 · Cited by 150 · cited 1×
“Chenodeoxycholic acid (CDCA) is the major activator of FXR, followed by deoxycholic acid (DCA), colic acid (LCA), and cholic acid (CA) (Jones et al., 2014).”
BackgroundVSL#3 can prevent ulcerative colitis-associated carcinogenesis in mice
Wang, C.-S.-E., Li, W., Wang, H., Ma, Y., Zhao, X., Yang, H., Qian, J., & Li, J. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i37.4254 · Cited by 150 · cited 1×
“However, the mesalazine group could significantly increase the abundance of Akkermansia and Lachnoclostridium, two beneficial bacteria negatively correlated with UC activity (Wang et al., 2018; Bian et al., 2019).”
BackgroundHuang, L., Zheng, J., Sun, G., Yang, H., Sun, X., Yao, X., Lin, A., & Liu, H. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04471-3 · Cited by 146
Self-citationLabbé, A., Ganopolsky, J. G., Martoni, C. J., Prakash, S., & Jones, M. L. (2014) · PLoS ONE · doi:10.1371/journal.pone.0115175 · Cited by 145 · cited 1×
“Gut microbiota analyses revealed that Firmicutes, Actinobacteria, and Erysipelotrichaceae have high BSH activity (Jones et al., 2008; Labbé et al., 2014).”
BackgroundNeff, C. P., Rhodes, M. E., Arnolds, K. L., Collins, C. B., Donnelly, J., Nusbacher, N., Jedlicka, P., Schneider, J. M., McCarter, M. D., Shaffer, M., et al. (2016) · Cell Host & Microbe · doi:10.1016/j.chom.2016.09.002 · Cited by 138 · cited 13×
“IBD includes two types: ulcerative colitis (UC) and Crohn’s disease (CD), both of which are associated with gut dysbiosis that occurs after the intestinal microbiota undergoes compositional and metabolic changes (Ni et al., 2017; Shen et al., 2018).”
BackgroundInfluentialMetabolomic analysis in inflammatory bowel disease: A systematic review
Gallagher, K., Catesson, A., Griffin, J. L., Holmes, E., & Williams, H. R. T. (2021) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjaa227 · Cited by 133 · cited 1×
“BA metabolism is defective in patients with IBD, as indicated by increased levels of primary BAs (PBAs) and/or their conjugated forms, accompanied by decreased levels of second BAs (SBAs) (Lavelle and Sokol, 2020; Biagioli et al., 2021; Gallagher et al., 2021).”
BackgroundKumar, R., Grover, S., & Batish, V. K. (2012) · Probiotics and Antimicrobial Proteins · doi:10.1007/s12602-012-9101-3 · Cited by 123 · cited 1×
“BSH activity was determined bymeasuring the amount of amino acids released from conjugated bile salts, as previously described with minor modifications (Kumar et al., 2012).”
MethodA model for the role of gut bacteria in the development of autoimmunity for type 1 diabetes
Davis-Richardson, A. G., & Triplett, E. W. (2015) · Diabetologia · doi:10.1007/s00125-015-3614-8 · Cited by 122 · cited 1×
“dorei in different disease models is also controversial (Sánchez et al., 2010; Davis-Richardson et al., 2014; Davis-Richardson and Triplett, 2015; Zhang et al., 2015; Yao et al., 2018; Yoshida et al., 2018; Song et al., 2021).”
BackgroundNLRP3-Dependent and -Independent Processing of Interleukin (IL)-1β in Active Ulcerative Colitis
Ranson, N., Veldhuis, M., Mitchell, B., Fanning, S. B., Cook, A. L., Kunde, D., & Eri, R. D. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms20010057 · Cited by 105 · cited 1×
“In active UC, NLRP3, and IL-1β are expressed mainly in lamina propria immune cells (Ranson et al., 2018).”
BackgroundBile acids activated receptors in inflammatory bowel disease
Biagioli, M., Marchianò, S., Carino, A., Di Giorgio, C., Santucci, L., Distrutti, E., & Fiorucci, S. (2021) · Cells · doi:10.3390/cells10061281 · Cited by 103 · cited 1×
“BA metabolism is defective in patients with IBD, as indicated by increased levels of primary BAs (PBAs) and/or their conjugated forms, accompanied by decreased levels of second BAs (SBAs) (Lavelle and Sokol, 2020; Biagioli et al., 2021; Gallagher et al., 2021).”
BackgroundKe, H., Li, F., Deng, W., Li, Z., Wang, S., Lv, P., & Chen, Y. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.726707 · Cited by 101 · cited 1×
“Mouse gut microbiota were depleted as previously described with minor modifications (Ke et al., 2021).”
MethodIntestinal Bacteroides species associated with coeliac disease
Sánchez, E., Donat, E., Ribes-Koninckx, C., Calabuig, M., & Sanz, Y. (2010) · Journal of Clinical Pathology · doi:10.1136/jcp.2010.076950 · Cited by 95 · cited 1×
“dorei in different disease models is also controversial (Sánchez et al., 2010; Davis-Richardson et al., 2014; Davis-Richardson and Triplett, 2015; Zhang et al., 2015; Yao et al., 2018; Yoshida et al., 2018; Song et al., 2021).”
BackgroundInflammatory bowel disease – non-biological treatment
Magro, F., Cordeiro, G., Dias, A. M., & Estevinho, M. M. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.105075 · Cited by 77 · cited 1×
“dorei BDX-01 treatment was also compared with mesalazine, a first-line agent in patients with active UC (Magro et al., 2020).”
ResultRole of bile acids in inflammatory bowel disease
Tiratterra, E. (2018) · Annals of Gastroenterology · doi:10.20524/aog.2018.0239 · Cited by 72 · cited 1×
“Dysregulation of BAmetabolism disrupts intestinal homeostasis by causing immune imbalance and dysbacteriosis, which lead to gut damage (Tiratterra et al., 2018).”
BackgroundImmunomodulatory functions of FXR
Fiorucci, S., Zampella, A., Ricci, P., Distrutti, E., & Biagioli, M. (2022) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2022.111650 · Cited by 70 · cited 1×
“The various bile acids activate several nuclear receptors in the gut: the TGR5 that is activated by LCA andDCA; the PXR that are activated by CDCA, LCA, and DCA; and the VDR that is activated by LCA and DCA, in addition to vitaminD (Fiorucci et al., 2022).”
BackgroundOgilvie, L. A., & Jones, B. V. (2012) · Gut · doi:10.1136/gutjnl-2012-302137 · Cited by 61 · cited 1×
“The gut microbiota of patients with IBD is characterized by low BSH activity (Ogilvie and Jones, 2012; Duboc et al., 2013).”
BackgroundA Novel Immunobiotics Bacteroides dorei Ameliorates Influenza Virus Infection in Mice
Song, L., Huang, Y., Liu, G., Li, X., Xiao, Y., Liu, C., Zhang, Y., Li, J., Xu, J., Lu, S., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.828887 · Cited by 56 · cited 2×
“dorei in different disease models is also controversial (Sánchez et al., 2010; Davis-Richardson et al., 2014; Davis-Richardson and Triplett, 2015; Zhang et al., 2015; Yao et al., 2018; Yoshida et al., 2018; Song et al., 2021).”
BackgroundBile acids: Key players in inflammatory bowel diseases?
Kriaa, A., Mariaule, V., Jablaoui, A., Rhimi, S., Mkaouar, H., Hernandez, J., Korkmaz, B., Lesner, A., Maguin, E., Aghdassi, A., et al. (2022) · Cells · doi:10.3390/cells11050901 · Cited by 53 · cited 1×
“Bile acids (BAs) are microbiota-associated metabolites that regulate intestinal homeostasis and inflammation in UC (Kriaa et al., 2022).”
BackgroundProbing Clostridium difficile Infection in Complex Human Gut Cellular Models
Anonye, B. O., Hassall, J., Patient, J. D., Detamornrat, U., Aladdad, A. M., Schüller, S., Rose, F. R. A. J., & Unnikrishnan, M. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.00879 · Cited by 36 · cited 1×
“Bacteroides dorei is prevalent in the human gut microbiota and can inhibit the growth of the colonic pathogen Clostridium difficile (Anonye et al., 2019), improve host resistance to influenza virus infection (Song et al.”
BackgroundBacterial metabolites directly modulate farnesoid X receptor activity
Zhang, X., Osaka, T., & Tsuneda, S. (2015) · Nutrition & Metabolism · doi:10.1186/s12986-015-0045-y · Cited by 34 · cited 2×
“, 2018), and its metabolites regulate the expression of genes involved in FXR and BA homeostasis in a gene- and tissue-specific manner in dietinduced obese mice (Zhang et al., 2015).”
BackgroundPedersen, R. M., Marmolin, E. S., & Justesen, U. S. (2013) · Anaerobe · doi:10.1016/j.anaerobe.2013.08.004 · Cited by 31
Spirillum Ehrenberg 1832, 38AL
Krieg, N. R. (n.d.) · Bergey’s Manual® of Systematic Bacteriology · doi:10.1007/0-387-29298-5_204
Cited by
Gut microbiota and microbial metabolites for osteoporosis
Zheng, X.-Q., Wang, D.-B., Jiang, Y., & Song, C. (2024) · Gut Microbes · doi:10.1080/19490976.2024.2437247 · Cited by 97
New insights into microbial bile salt hydrolases: from physiological roles to potential applications
Dong, Z., Yang, S., Tang, C., Li, D., Kan, Y., & Yao, L. (2025) · Frontiers in Microbiology · doi:10.3389/fmicb.2025.1513541 · Cited by 64
Exploring the Probiotic Potential of Bacteroides spp. Within One Health Paradigm
Tufail, M. A., & Schmitz, R. A. (2024) · Probiotics and Antimicrobial Proteins · doi:10.1007/s12602-024-10370-9 · Cited by 75
Ulcerative colitis: signaling pathways, therapeutic targets and interventional strategies
Jia, J., Liu, Y., Wang, D., Pan, Z., Zheng, Q., Lu, J., Liang, C., & Li, D. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02345-1 · Cited by 69
Li, Z., Chu, T., Sun, X., Zhuang, S., Hou, D., Zhang, Z., Sun, J., Liu, Y., Li, J., & Bian, Y. (2024) · Food Chemistry · doi:10.1016/j.foodchem.2024.142391 · Cited by 54
Self-citation
Metadata
- Authors
- Sun, X., Chen, Z., Yu, L., Zeng, W., Sun, B., Fan, H., & Bai, Y.
- Affiliations
- Nanfang Hospital (CN)
- Southern Medical University (CN)
- Corresponding author
- Fan, Hongying
- Bai, Yang
- Venue
- Frontiers in Pharmacology
- Publisher
- Frontiers Media SA
- Published
- 2023-05-24
- Volume
- 14
- Pages
- 1205323-1205323
- ISSN
- 1663-9812 (ISSN-L)
- PMC
- PMC10244678
- OpenAlex
- W4378072401
- Semantic Scholar
- 1e771f77ac7c9d93e90db381a68de32c43ac9763
- Cited by
- 33
- References
- 64
- Citations by year
- 2026: 13 · 2025: 14 · 2024: 6
- FWCI
- 2.93
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Pharmacology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Natural Science Foundation of Guangdong Province (2021CR008)
- Nanfang Hospital (2021CR008)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Gastroenterology › Inflammatory Bowel Disease
- Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
- Keywords
- ulcerative colitis, DSS-induced colitis, bile salt hydrolase, bile acid metabolism, farnesoid X receptor, NLRP3 inflammasome, FGF15, gut microbiota, anti-inflammatory activity, deoxycholic acid, cholic acid, beta-muricholic acid, inflammatory cytokines
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.